<< Celgene to collaborate with PTC on advancing drug discovery efforts | Low HDL-cholesterol and high triglycerides linked to increased risk of CHD >>
Read in | English | Español | 日本語 | Finnish | हिन्दी | Русский | Svenska

Ten of ChemBridge's screening libraries available through CDD database

Published on September 3, 2009 at 7:29 AM · No Comments

ChemBridge Corporation, a leading discovery chemistry company offering an extensive portfolio of discovery chemistry products and contract research services, has now made ten of their most popular screening libraries available to researchers via the Collaborative Drug Discovery (CDD) Public Access database. Now for the first time, researchers can access ChemBridge Libraries alongside a growing body of public data from leading vendors, researchers, scientific literature, and patent resources. CDD subscribers can access the data directly from their private groups, mining the libraries using their own private data to more effectively identify compounds of interest within the ChemBridge datasets, increasing the efficiency of identifying drug candidates. "The CDD database is an effective platform for biological and chemical data storage and mining, and knowing that a number of our client companies and research organizations are actively using the CDD database, we wanted to ensure that our clients could easily integrate ChemBridge screening library data into their workflow within the CDD database," said Duncan Beniston, Executive Director Sales & Marketing, ChemBridge.

The libraries being offered include ChemBridge's DIVERSet(TM), a 50,000 diverse small molecule dataset covering a broad range of pharmacophore space , CNS-Set(TM), containing 56,000 molecules with an increased probability of blood brain barrier penetration, as well as eight other libraries from ChemBridge's impressive portfolio. In total, more than 600,000 ChemBridge molecules will be available through the CDD Database. "The CDD community for private access and the entire researcher community for public access both benefit when valuable new molecules and data are added to the database, such as the latest compounds available right off the shelf from ChemBridge," says CDD CEO Barry Bunin, PhD, "and experimental and computational scientists with this new technology can view whole libraries and drill down to individual compounds from multiple data feeds. It is a new way of simultaneously interacting with lots of data from lots of collaborations."

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading